CA72-4

Aliases
  • CA72-4
  • Cancer-associated Antigen 72-4
  • TAG-72
  • tumor-associated glycoprotein 72
Description
High-MW mucin-type glycoprotein expressed on epithelial cancer cells.
Attributes
QA State
Accepted
Type
Protein
Certifications
  • None
QA State for Breast
Under Review

 Non-Public Biomarker

Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.

Certifications
  • None
QA State for Ovary
Accepted
Organ-Specific Notes

Overexpression (protein) studies in ovarian cancer.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. CA72-4 alone was not a strong predictor.

Supporting Study Data
PLCO Ovarian Phase III Validation Study
Study phase on the ovary: 3

Our preliminary data indicate that the performance of CA 125 as a screening test for ovarian cancer can be improved upon by additional biomarkers. With completion of one additional validation step, we will be ready to test the performance of a consensus marker panel in a phase III validation study. Given the original aims of the PLCO trial, we believe that the PLCO represents an ideal longitudinal cohort offering specimens for phase III validation of ovarian cancer biomarkers.

View Protocol
Decision rule: PMID:21372037
SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study
Study phase on the ovary: 3

Create a new set of phase II specimens (160 cases with pre-operative bloods representing major histologic types and including 80 early-staged and 80 late-staged cases, 160 controls with benign disease, 480 general population controls, and a small set of serial Samples collected either at least 3 months apart, but not more than 6 months apart OR between 10 months apart and no more than 14 months apart in 40 healthy controls) will be used to evaluate markers identified in preliminary work. The top 5-10 markers, plus an expanded panel of Luminex markers, will comprise a “working consensus panel” for subsequent analysis in PLCO specimens.

View Protocol
Decision rule: PMID:21372037
Ovary-Specific Protocols
  • No organ-level protocols specified for ovary.
Ovary-Specific Publications
  • No organ-level publications were listed for ovary.
Ovary-Specific Resources
  • No organ-level resources were given for ovary.
  • No resources were specified for this biomarker.